LUX July 2017

LUX - July 2017 67 You’re in Trouble Femeda’s CEO, Andrew Tasker has over 30 years’ experience in consumer healthcare, medical devices and pharmaceuticals, including working for Procter and Gamble, Boots, Bausch and Lomb and in MD roles at Pfizer Consumer Healthcare and Mentholatum. He has worked across multiple health care sectors in the UK, Europe, and Middle East Africa, launching new multiple new technologies and innovations. Femeda has filed over fifty patent applications, via several patent families to protect the unique aspects of the Pelviva device that contribute to its efficacy and comfort. The firm’s CEO, Andrew Tasker explains how the product works, plus the strong investor support and the supporting evidence they have for it. “Pelviva has been developed to be very easy to use with just a pull tab to get it started. Made of soft foam, each Pelviva contains a micro-processor that delivers the unique Pelviva reactive pulse technology to the pelvic floor muscles. “Since Femeda was founded, investors have been extremely supportive of the vision and ambition demonstrated by the business; most of the founding investors remain with the business today. This support has been actively demonstrated in several funding rounds over the past years. “In a 12-week clinical study, 84% of women using Pelviva experienced an improvement in bladder control. Women using Pelviva for 12 weeks - experienced a four times greater reduction in the impact that bladder leaks had on their lives - when compared to women doing unsupervised pelvic floor muscle exercises.” In closing, Andrew details the prevalence of the problem, in his own words. “There are three main types of urinary incontinence that affect women, of these, stress urinary incontinence is the most prevalent. On stress urinary incontinence (SUI), this concerns the complaint of involuntary leakage on effort or exertion, or on sneezing or coughing. “Secondly, urgency urinary incontinence (UUI) is the complaint of involuntary loss of urine, associated with urgency, usually with frequency and nocturia and is clinically described as: overactive bladder syndrome - OAB. “Thirdly, mixed urinary incontinence is the complaint of involuntary leakage associated with urgency and with exertion, effort, sneezing or coughing. Pelviva treats all three types of incontinence in one simple session” Femeda is a UK based company focused on development of medical devices for female urinary incontinence. Currently in the final stages of development, Pelviva is a life-changing technological breakthrough, for the treatment of weak pelvic floor muscles that cause bladder leaks in women. We interviewed the firm’s CEO, Andrew Tasker to discover more. Company: Femeda Ltd Name: Andrew Tasker Email: [email protected] Web Address: www.femeda.com Address: Unit 9, Nelson Park, Colbourne Avenue, Cramlington, NE23 1WD UK Telephone: +44 (0)330 043 2071